Improper title. 1. This is specifically about non-SCLC. 2. This article is entirely about a downside to receiving PD-1/PDL-1 inhibitor biologics as immunother

Improper title. 1. This is specifically about non-SCLC. 2. This article is entirely about a downside to receiving PD-1/PDL-1 inhibitor biologics as immunotherapy; that approximately a third of patients develop HPD and should be switched to salvage chemotherapy as soon as this is noted.